Drug Profile
HIV vaccine vCP205
Alternative Names: ALVAC vCP205; ALVAC-HIV vCP205; vCP205Latest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections in USA (IM)
- 01 Jan 2008 Phase-I clinical trials in HIV-1 infections in USA (IM)
- 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur